Physician profile
Nitin S Butala
NPI 1740483882
$15,479.62
in general payments reported to CMS, 2019-2025
53 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,952 · 2020: $1,986 · 2021: $2,929 · 2022: $3,110 · 2023: $5,503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,500 · Travel and Lodging: $2,481 · Food and Beverage: $521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,500.00 |
| Travel and Lodging | $2,481.35 |
| Food and Beverage | $521.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $5,309.71 | 2022-2023 | Adlarity |
| Teva Pharmaceuticals USA, INC. | $918.36 | 2019-2023 | Ajovy |
| Amgen INC. | $902.34 | 2019-2023 | Aimovig |
| Allergan, INC. | $752.47 | 2019-2021 | |
| Abbvie INC. | $563.78 | 2019-2023 | Qulipta |
| Biogen, INC. | $467.43 | 2019-2022 | |
| Genzyme Corporation | $425.63 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $409.83 | 2019-2023 | Ultomiris |
| Horizon Therapeutics Plc | $403.70 | 2021-2022 | |
| Eisai INC. | $394.88 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $376.38 | 2019-2022 | |
| Adamas Pharmaceuticals, INC. | $343.69 | 2019-2021 | |
| Ucb, INC. | $338.30 | 2019-2022 | |
| Csl Behring | $298.46 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $254.58 | 2020-2021 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitin Butala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.